Li Yang

Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million.

Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China.